Cerebral Venous Sinus Thrombosis in Women: Subgroup Analysis of the VENOST Study

Table 4

Etiological factors and outcome of subgroups according to reproductive health-related risks.

Compared data of reproductive health-related risk factors	Pregnancy		Puerperium		Oral contraceptive use
						%
Infections
Paracranial (focal)	2	3	4	3	7	7	0.589
Systemic	1	1	3	2	1	1
History of VTE
Cerebral	0^a	0	1a	1	1^a	1
Deep venous thrombosis	3^a	4	0^b	0	0^b	0	0.030
Other	0^a	0	2^a	1	0^a	0
Malignancy	0	0	1	1	0	0	0.526
Family history VTE	1	1	0	0	0	0	0.228
MTHFR mutation
Heterozygote, homozygote	1	2	5	5	3	5	0.385
Hyperhomocysteinemia	1	2	7	7	1	2	0.204
Prothrombin mutation	0	0	5	4	4	5	0.240
Protein C/S deficiency	0	0	3	3	4	6	0.361
Factor V Leiden mutation	3	5	8	7	2	2	0.335
Thrombocytosis	4	9	3	3	4	6	0.716
Polycythemia vera	1	2	1	1	0	0	0.241
Anticardiolipin Ab	0	0	0	0	0	0	—
PAI mutation	0	0	1	1	0	0	0.517
Antithrombin III deficiency	0	0	1	1	1	2	0.718
Hyperfibrinogenemia	0	0	0	0	1	1	0.568
Antiphospholipid Ab	2	3	0	0	0	0	0.057
Activated protein C	1	2	3	3	0	0	0.362
Resistance	1	2	1	1	2	2	0.821
High ANA titers	0	0	4	4	0	0	0.122
First month Rankin
0-1	49	78	102	78	85	86	0.177
2	7	11	18	14	12	12
>3	7	11	11	8	2	2
Third month Rankin
0-1	45	92	103	89	79	94
2	3	6	10	9	4	5	0.828
>3	1	2	3	3	1	1
Sixth month Rankin
0-1	44	96	100	94	71	97
2	1	2	4	4	1	1	0.937
>3	1	2	2	2	1	1
12th month Rankin
0-1	34	97	87	95	64	100
2	1	3	3	3	0	0	0.409
>3	0	0	2	2	0	0

ANA: antinuclear antibody; MTHFR: methylenetetrahydrofolate reductase; PAI: plasminogen activator inhibitor; VTE: venous thromboembolism.